vivexia
securing healthcare innovation

Staphylococcus aureus – Sepsis (peritonitis)

Procedure Summary

- Immunocompetent CD-1 mice, eight weeks old females
- *Staphylococcus aureus* ATCC 29213
- Bacterial challenge by intraperitoneal route
- Mucin 5%
- Reference compound: Amoxicillin (IP), Ciprofloxacin (IP), anti-infective peptides (IP)

Experimental readouts

- Survival rate
- Weight loss
- Clinical score

Optional Services

- CFU determination (peritoneal fluid, spleen…)
- Cytokine and chemokine analysis
- Pharmacokinetics

Animal Welfare

- Each experimental protocol is approved by the local ethics committee for animal experimentation of Grand Campus Dijon (Burgundy, France) and performed in accordance to the current recommendations of the European Institute of Health EU Directive 86/609

Facilities

- These assays are performed at our BSL2 laboratory / zootechnical center in Dijon, France

Reference

- Internal Data
- Scott *et al.*, Nature Biotech 2010 "An anti-infective peptide that selectively modulates the innate immune response"

Efficacy of ciprofloxacin and amoxicillin on survival rate in a murine model of septicaemia induced by *Staphylococcus aureus* ATCC 29213



Our scientific team will readily accomodate client-specific alterations and will provide expert advice and guidance for your efficacy studies

For more information please contact: **info@vivexia.fr**